收藏切换
The improvement provided by harpagoside on metabolic dysfunction-associated steatohepatitis in mice
收藏切换
Xiao-yi WANG1, Ke-ke WANG1, Wang-ya JIA1, Jian LI2, 3, Hong XU1, *, Li-li JI1, *
Acta Pharmaceutica Sinica | 2026, 61(1) : 163 - 172
Less
收藏切换
Acta Pharmaceutica Sinica | 2026, 61(1): 163-172
• Original Articles •
The improvement provided by harpagoside on metabolic dysfunction-associated steatohepatitis in mice
Full
Xiao-yi WANG1, Ke-ke WANG1, Wang-ya JIA1, Jian LI2, 3, Hong XU1, *, Li-li JI1, *
Affiliations
  • 1The MOE Key Laboratory for Standardization of Chinese Medicines, The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
  • 2Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China
  • 3Technology Center of Jinling Pharmaceutical Co., Ltd., Nanjing 210009, China
Published: 2026-01-12 doi: 10.16438/j.0513-4870.2025-0324
Outline
收藏切换

Harpagoside (HPG) is an iridoid compound derived from Scrophularia ningpoensis Hemsl. This study aimed to investigate the therapeutic effect of HPG on metabolic dysfunction-associated steatohepatitis (MASH) and elucidate its underlying mechanisms. MASH was induced in mice using a methionine-choline-deficient diet (MCD). The efficacy of HPG in improving MASH was assessed through serum biochemical indexes, liver pathological changes, oxidative stress markers, and inflammatory responses (this experiment was approved by the Laboratory Animal Ethics Committee of Shanghai University of Traditional Chinese Medicine, with approval number PZSHUTCM2305180005). To further explore the mechanism of action, Western blot (WB), quantitative real-time polymerase chain reaction (qPCR), and in vitro cell models were employed. The results demonstrated that HPG (30 and 60 mg·kg-1) significantly mitigated liver damage (P < 0.05, P < 0.001), reduced hepatic lipid accumulation (P < 0.05, P < 0.001), lowered the elevated non-alcoholic fatty liver disease (NAFLD) activity score (NAS) (P < 0.05, P < 0.01, P < 0.001), alleviated hepatic oxidative stress injury, and suppressed hepatic inflammation in MCD-induced MASH mice (P < 0.05, P < 0.01, P < 0.001). WB and qPCR analyses revealed that HPG promoted the nuclear accumulation of nuclear factor erythroid 2-related factor 2 (Nrf2) in the livers of MCD-fed mice and in AML-12 cells (P < 0.05). Additionally, it reduced the nuclear accumulation of nuclear factor kappa B (NF-κB) in the livers of MCD-fed mice and in THP-1 cells (P < 0.05). Collectively, these findings suggest that HPG improves MASH through alleviating liver oxidative and inflammatory injury by activating Nrf2 antioxidant signaling pathway and inhibiting NF-κB inflammatory signaling pathway.

harpagoside  /  metabolic dysfunction-associated steatohepatitis  /  oxidative stress  /  inflammation  /  nuclear factor erythroid 2-related factor 2  /  nuclear factor kappa B signaling pathway
王筱懿, 王可可, 贾王雅, 李剑, 徐红, 季莉莉. 哈巴俄苷改善小鼠代谢功能障碍相关脂肪性肝炎的研究. 药学学报, 2026 , 61 (1) : 163 -172 . DOI: 10.16438/j.0513-4870.2025-0324
Xiao-yi WANG, Ke-ke WANG, Wang-ya JIA, Jian LI, Hong XU, Li-li JI. The improvement provided by harpagoside on metabolic dysfunction-associated steatohepatitis in mice[J]. Acta Pharmaceutica Sinica, 2026 , 61 (1) : 163 -172 . DOI: 10.16438/j.0513-4870.2025-0324
Year 2026 volume 61 Issue 1
186
95
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2025-0324
  • Receive Date:2025-03-24
  • Online Date:2026-09-21
  • Published:2026-01-12
Article Data
Affiliations
History
  • Received:2025-03-24
  • Revised:2025-07-08
Affiliations
    1The MOE Key Laboratory for Standardization of Chinese Medicines, The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
    2Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China
    3Technology Center of Jinling Pharmaceutical Co., Ltd., Nanjing 210009, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2025-0324
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT